Video
Dr. Epperla on Treatment Following Ibrutinib in MCL
Author(s):
Narendranath Epperla, MBBS, MS, hematologist, The Ohio State University (OSU) Comprehensive Cancer Center, assistant professor in internal medicine, OSU, discusses the next steps for patients with mantle cell lymphoma (MCL) who fail ibrutinib (Imbruvica).
Narendranath Epperla, MBBS, MS, hematologist, The Ohio State University (OSU) Comprehensive Cancer Center, assistant professor in internal medicine, OSU, discusses the next steps for patients with mantle cell lymphoma (MCL) who fail ibrutinib (Imbruvica).
Patients who fail ibrutinib have poor results, with the median survival being a few months. As of today, there is no breakthrough treatment for patients who fail ibrutinib, which is an urgent unmet need, states Epperla.
There are ongoing combination trials investigating ibrutinib with CDK4/6 inhibitors to determine if that can overcome resistance, explains Epperla.
